Yield10 Story

YTEN -- USA Stock

USD 14.35 2.15 13.03%

Macroaxis Story

Despite quite sluggish fundamental indicators, Yield10 Bioscience may actually be approaching a critical reversion point that can send shares even higher in February 2021. Will institutional investors continue to hold, or should we expect a sell-off?

Published over a month ago

View all stories for Yield10 Bioscience | View All Stories

Does Yield10 Bioscience (NASDAQ:YTEN) have persistent fundamental indicators based on the latest rise?

Yield10 Bioscience is FAIRLY VALUED at 13.80 per share with modest projections ahead. Yield10 Bioscience is moderately volatile given 1 month investment horizon. Yield10 Bioscience shows Sharpe Ratio of 0.16, which attests that the company had 0.16% of return per unit of risk over the last month. Our standpoint towards determining the risk of a stock is to use both market data as well as company specific technical data. We were able to break down twenty-one different technical indicators, which can help you to evaluate if expected returns of 1.64% are justified by taking the suggested risk. Use Yield10 Bioscience Downside Deviation of 3.23, market risk adjusted performance of (23.43), and Mean Deviation of 3.78 to evaluate company specific risk that cannot be diversified away.

Typically, a company's financial statements are the reports that show the financial position of the company. There are three main documents that fall into the category of financial statements. These documents include Yield10 Bioscience income statement, its balance sheet, and the statement of cash flows. Potential Yield10 Bioscience investors and stakeholders use financial statements to determine how well the company is positioned to perform in the future. Although Yield10 Bioscience investors may use each financial statement separately, they are all related. The changes in Yield10 Bioscience's assets and liabilities, for example, are also reflected in the revenues and expenses that we see on Yield10 Bioscience's income statement, which results in the company's gains or losses. Cash flows can provide more information regarding cash listed on a balance sheet, but not equivalent to net income shown on the income statement. Please read more on our technical analysis and fundamental analysis pages.

The goal of Yield10 Bioscience fundamental analysis is to do accurate financial forecasts. There are several possible objectives to fundamental analysis, such as projecting of Yield10 Bioscience performance into the future periods or doing a reasonable stock valuation. The intrinsic value of Yield10 Bioscience shares is the value that is considered the true value of the share. If the intrinsic value Yield10 is higher than its market price, buying is generally recommended. If it is equal to the market price, it is recommended to hold; and if it is less than the market price, then one should sell all shares Yield10 Bioscience.

Please read more on our fundamental analysis page.

What is Yield10 Asset Breakdown?

Yield10 Bioscience reports assets on its Balance Sheet. It represents the amount of Yield10 resources that either has an existing economic value or will provide some form of benefits in the future. To get a better handle on how balance sheet or income statements item affect Yield10 volatility, please check the breakdown of all its fundamentals

Are Yield10 Bioscience Earnings Expected to grow?

The future earnings power of Yield10 Bioscience involves the interaction of many company-specific, industry, and economic forces. Earnings estimates embody investors' opinions of Yield10 Bioscience factors such as sales growth, product demand, competitive industry environment, profit margins, and cost controls. Yield10 Bioscience stock prices adjust as these expectations change or are proven wrong. The main thing to remember is that equities with high expected earnings growth tend to underperform the market because it is usually difficult to meet the market's high expectations. Companies with low earnings expectations tend to do better than expected. Please use our latest analysis of Yield10 expected earnings.

Yield10 Bioscience Gross Profit

Yield10 Bioscience Gross Profit growth is one of the most critical measures in evaluating the company. The Gross Profit growth rate is calculated simply by comparing Yield10 Bioscience previous period's values with its current period's values. Each time period you're measuring should be of equal lengths the increase or decrease, in a company's Gross Profit between two periods. Here we show Yield10 Bioscience Gross Profit growth over the last 10 years.

Please check Gross Profit in more details.

Yield10 Bioscience exotic insider transaction detected

Legal trades by Yield10 Bioscience insiders are very common, as founders, directors, or employees of any publicly traded firm often have stock or stock options. These trades are made public in the United States through the filing of Form 4 of the Securities and Exchange Commission. Below entry was recorded recently and is publicly available as an insider trade:

Yield10 insider trading alert for general transaction of common stock by Kristi Snell, VP Research & CSO, on 16th of February 2021. This event was filed by Yield10 Bioscience Inc with SEC on 2021-02-16. Statement of changes in beneficial ownership - SEC Form 4. Kristi Snell currently serves as chief science officer, vice president - research of Yield10 Bioscience [view details]

Note, although insider trading is legal, in the United States, Canada, Australia, and Germany, for mandatory reporting purposes, corporate insiders are defined as a company's officers, directors, and any beneficial owners of more than 10% of a class of the company's equity securities.

Is Yield10 Bioscience valued adequately by the market?

Although in the United States, the Securities and Exchange Commission has enforced strong rules to prevent insiders from engaging in insider trading, finding insiders among active shareholders of Yield10 Bioscience is not uncomon. Institutional investors typically avoid acquiring a high percentage of Yield10 Bioscience stocks because performing such an act may violate securities laws. They are usually not investing their own money, but rather making investments on behalf of their clients. Let's take a look at how the ownership of Yield10 is distributed among investors.

Ownership Allocation

The market capitalization of Yield10 Bioscience is $23.04 Million. Yield10 Bioscience owns significant amount of outstanding shares owned by insiders. An insider is usually defined as a CEO, other corporate executive, director, or institutional investor who own at least 10% of the company outstanding shares. Since such a large part of the company is owned by insiders, it is advisable to analyze if each of these insiders have been buying or selling the stock in recent months. Note, that even with negative profits, if the true value of the company is larger than the current market value, you may still be able to generate positive returns on investment in this company.

Retail Investors

61.18%

Insiders

30.45%

Institutions

8.37%

	Retail Investors	61.18
	Insiders	30.45
	Institutions	8.37

	2020	2021 (projected)
Interest Expense	11.5 K	11.8 K
Gross Profit	1.04 M	1.07 M

Interest Expense Gross Profit

Asset Utilization

The asset utilization indicator refers to the revenue earned for every dollar of assets a company currently reports. Yield10 Bioscience has an asset utilization ratio of 4.35 percent. This suggests that the company is making $0.0435 for each dollar of assets. An increasing asset utilization means that Yield10 Bioscience is more efficient with each dollar of assets it utilizes for everyday operations.

Current Assets

9.3 M

Assets Non Current

3.9 M

	Current Assets	9.28 Million	70.33
	Assets Non Current	3.91 Million	29.67

Yield10 Bioscience implied volatility may change after the rise

Mean deviation is down to 3.78. It may entail a possible volatility slide. Yield10 Bioscience is displaying above-average volatility over the selected time horizon. Investors should scrutinize Yield10 Bioscience independently to ensure intended market timing strategies are aligned with expectations about Yield10 Bioscience volatility.

Our Takeaway on Yield10 Bioscience Investment

Whereas many of the other players under the agricultural inputs industry are still a bit expensive, Yield10 Bioscience may offer a potential longer-term growth to institutional investors. On the whole, as of the 17th of January 2021, our research shows that Yield10 Bioscience is a rather moderately volatile investment opportunity with a high odds of distress in the next two years. From a slightly different view, the entity currently appears to be fairly valued. However, our primary 30 days advice on the company is Strong Sell.

About Contributor

Ellen Johnson is a Member of Macroaxs Editorial Board. Ellen covers public companies in North America, focusing primarily on valuation and volatility. Six years of experience in predictive investment analytics and risk management. View Profile

This story should be regarded as informational only and should not be considered a solicitation to sell or buy any financial products. Macroaxis does not express any opinion as to the present or future value of any investments referred to in this post. This post may not be reproduced without the consent of Macroaxis LLC. Macroaxis LLC and Ellen Johnson do not own shares of Yield10 Bioscience. Please refer to our Terms of Use for any information regarding our disclosure principles.

Would you like to provide feedback on the content of this article?

You can get in touch with us directly or send us a quick note via email to editors@macroaxis.com

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2021 Macroaxis LLC